Stuart Orkin Wins Brinster Prize for Sickle Cell Gene Therapy Breakthrough

Stuart Orkin spent decades asking a deceptively simple question: why does the human body switch off one gene and turn on another at birth? The answer to that question, pursued through years of laboratory work at Harvard Medical School, has now earned him the Elaine Redding Brinster Prize, awarded by the University of Pennsylvania's Institute for Regenerative Medicine.

The gene in question produces fetal hemoglobin, the oxygen-carrying protein that sustains a developing fetus in the womb. At birth, the body ordinarily silences this gene and activates adult hemoglobin instead—a molecular handoff so routine that most of us never think about it. But Orkin did think about it, and he wanted to understand the precise mechanisms that made the switch happen. That curiosity about basic biology would eventually lead somewhere unexpected: a therapy that could help people with sickle cell disease and other blood disorders by reactivating the fetal hemoglobin gene in adults.

The connection between these two things—understanding gene regulation and treating disease—is not automatic. Many researchers spend their careers on fundamental questions without ever seeing their work translated into medicine. Orkin's distinction is that he did both. His discoveries about how fetal hemoglobin is regulated revealed unexpected details about gene control that suggested a therapeutic angle. He then took that insight and applied modern gene-editing technologies to develop a specific clinical application. It is the kind of arc that institutions like to celebrate: pure science becoming applied science, becoming medicine.

Orkin, who holds the David G. Nathan Distinguished Professor title at Harvard Medical School and is an investigator with the Howard Hughes Medical Institute, will receive $100,000, a commemorative medal, and an invitation to deliver a ceremonial lecture at Penn. He will accept the prize on March 13, 2024, during the Ralph L. Brinster Symposium, a day-long gathering of prominent biomedical researchers from institutions including Rockefeller University, Stanford, the Stowers Institute, and Caltech.

The Brinster Prize, now in its third year, is supported by an endowment from the children of Elaine Redding Brinster and is awarded annually to a researcher whose singular discovery has made a unique impact on biomedicine. Previous recipients include molecular biologist C. David Allis and neurogeneticist Huda Zoghbi. Ken Zaret, director of Penn's Institute for Regenerative Medicine, noted that Orkin's work exemplifies how a career devoted to understanding the mechanisms of gene regulation can be channeled into methods for treating devastating human diseases.

Orkin's honors extend well beyond this prize. He has received the Canada Gairdner International Award, the Gruber Foundation Prize in Genetics, the King Faisal Prize in Medicine, and the Kovaleno Medal from the National Academy of Sciences, among others. He is a member of both the U.S. National Academy of Medicine and the National Academy of Sciences. In his response to the Brinster Prize, Orkin expressed humility about the recognition and hope that his laboratory's work would inspire others to pursue fundamental discovery with patient benefit in mind.

The significance of this work extends beyond the laboratory. Sickle cell disease affects millions of people worldwide, with particularly high prevalence in African and African-American populations. The condition causes severe pain, organ damage, and shortened life expectancy. A therapy that can reactivate fetal hemoglobin in adult patients offers the possibility of meaningful relief from a disease that has long resisted treatment. Orkin's prize recognizes not just the intellectual achievement of understanding gene switching, but the translation of that understanding into a tool that could change lives.